Tacrolimus 0.12%

Route: Topical application to affected skin.

• Apply a thin layer to the affected area(s) twice daily as directed by the prescriber.
• Rub in gently and completely; do not occlude (avoid wrapping with bandages unless specifically directed).
• Wash hands before and after application, unless hands are the treatment area.
• Do not apply to eyes or mucous membranes.
• Can be applied to face, neck, and intertriginous areas where corticosteroids carry high atrophy risk.
• Avoid UV light exposure to treated areas; use sunscreen or protective clothing.

Applied topically twice daily to affected areas until clear or near-clear, then reduced to once daily or as-needed maintenance per prescriber direction. The 0.12% concentration is prescriber-determined for patients requiring additional efficacy beyond standard commercial strengths. Duration of treatment is individualized; short courses for flares or chronic intermittent use for remission maintenance are both appropriate contexts.

• Tacrolimus (topical calcineurin inhibitor): Tacrolimus binds to the cytoplasmic immunophilin FKBP-12, forming a tacrolimus-FKBP-12 complex that competitively inhibits calcineurin (a serine-threonine phosphatase). Calcineurin normally dephosphorylates NFAT in T-cell cytoplasm, allowing NFAT nuclear translocation and transcription of cytokine genes. By blocking calcineurin, tacrolimus prevents NFAT activation → reduced synthesis of IL-2, IL-4, IL-5, IL-10, IFN-γ, and TNF-α by T cells and mast cells. Additionally suppresses FcεRI-mediated mast cell and basophil activation. Unlike topical corticosteroids, tacrolimus does not downregulate collagen synthesis or impair epidermal barrier formation, eliminating the risk of skin atrophy, striae, and telangiectasia with long-term use.

Indication context: Tacrolimus 0.12% is prescribed for moderate-to-severe atopic dermatitis (eczema), seborrheic dermatitis, allergic contact dermatitis, and other T-cell-driven inflammatory dermatoses, particularly in areas where topical corticosteroids are high-risk (face, eyelids, intertriginous areas, neck). The 0.12% concentration is selected when standard commercial concentrations (0.1% Protopic) have provided insufficient response, or when the prescriber determines a higher concentration is clinically appropriate for the severity of disease.

Monitoring:

• Assess treatment area for clinical improvement (erythema, pruritus, lichenification) at 2–4 weeks.
• Monitor for application site reactions (burning, stinging—typically transient).
• For long-term use: consider periodic skin examination to monitor for any unusual lesions (FDA black box warning re: theoretical malignancy risk with prolonged use).
• Systemic tacrolimus blood levels are generally undetectable with topical application on intact skin; monitoring is not typically required for topical use.

Contraindications:

• Active skin infections at the application site (bacterial, viral, or fungal); treat infection before initiating tacrolimus.
• Netherton syndrome or other conditions causing significantly impaired skin barrier (risk of systemic absorption).
• Known hypersensitivity to tacrolimus or any component of the formulation.

Warnings & Precautions:

• FDA Black Box Warning (class effect for topical calcineurin inhibitors): Long-term safety not established; rare cases of lymphoma and skin malignancy reported in patients using topical calcineurin inhibitors; avoid continuous long-term use; not recommended in immunocompromised patients or children under 2 years.
• UV exposure: avoid intentional sun exposure (tanning beds) on treated areas; the immunosuppressive effect may theoretically impair UV-induced DNA repair.
• Alcohol ingestion: flushing and skin irritation may occur in treated areas if alcohol is consumed shortly after application (vasodilation effect).
• Herpes simplex and varicella infections: may be exacerbated or disseminated in immunosuppressed skin; monitor for viral skin infections during use.

Drug Interactions:

• CYP3A4 inhibitors (systemic): not relevant at topical concentrations with intact skin; relevant only with impaired skin barrier where systemic absorption may increase.

Common Side Effects: Application site burning (most common, especially first 1–2 weeks), pruritus, erythema, and stinging—typically decrease with continued use; folliculitis; rare skin infections; alcohol-related flushing.

Store at room temperature (15–25°C). Do not freeze. Keep away from light and heat. Keep container tightly closed. Use within the beyond-use date assigned by Genesis Compounding per USP <795> guidelines. Keep out of reach of children.

Why is this concentration higher than Protopic?

FDA-approved Protopic is available at 0.03% (for children 2–15 years and sensitive areas in adults) and 0.1% (for adults with moderate-to-severe atopic dermatitis). The 0.12% compounded concentration is prescribed when additional immunosuppressive activity is clinically indicated. The prescribing clinician determines whether the increased concentration is appropriate based on disease severity and prior treatment response.

Will this thin my skin like steroid creams?

No. Unlike topical corticosteroids, tacrolimus does not inhibit fibroblast collagen synthesis or impair epidermal cell turnover. Long-term use does not produce skin atrophy, striae, or telangiectasia, making it suitable for sensitive areas such as the face and skin folds.

What does the burning sensation mean?

A burning or stinging sensation is common in the first 1–2 weeks of use, especially on actively inflamed skin. It typically resolves as the inflammation improves. If burning is severe or persistent beyond 2 weeks, contact your prescriber.

Is this FDA-approved?

Tacrolimus ointment is FDA-approved (Protopic) at 0.03% and 0.1%. The 0.12% concentration is not commercially available; this is a patient-specific 503A compounded preparation from Genesis Compounding requiring a valid prescriber order.